Luigi Taranto-Montemurro
Overview
Explore the profile of Luigi Taranto-Montemurro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1249
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schwartz A, Herpel L, Bogan R, Corser B, Pho H, Taranto-Montemurro L
Sleep Breath
. 2024 Sep;
28(6):2571-2580.
PMID: 39305436
Background: Norepinephrine reuptake inhibitors such as atomoxetine (ato) can improve OSA by increasing pharyngeal muscle activity. Mineralocorticoid antagonists such as spironolactone, may potentiate the reduction of OSA severity and reduce...
2.
Schweitzer P, Taranto-Montemurro L, Ojile J, Thein S, Drake C, Rosenberg R, et al.
Am J Respir Crit Care Med
. 2023 Oct;
208(12):1316-1327.
PMID: 37812772
Obstructive sleep apnea (OSA) is a common sleep disorder for which the principal treatment option, continuous positive airway pressure, is often poorly tolerated. There is currently no approved pharmacotherapy for...
3.
Esmaeili N, Labarca G, Hu W, Vena D, Messineo L, Gell L, et al.
Ann Am Thorac Soc
. 2023 Aug;
20(11):1633-1641.
PMID: 37531573
Recent studies have shown that sleep apnea-specific intermittent hypoxemia quantified by the hypoxic burden (HB) predicted cardiovascular disease (CVD)-related mortality in community-based and clinical cohorts. Calculation of HB is based...
4.
Labarca G, Vena D, Hu W, Esmaeili N, Gell L, Yang H, et al.
Am J Respir Crit Care Med
. 2023 Jul;
208(7):802-813.
PMID: 37418748
Obstructive sleep apnea is characterized by frequent reductions in ventilation, leading to oxygen desaturations and/or arousals. In this study, association of hypoxic burden with incident cardiovascular disease (CVD) was examined...
5.
Gell L, Vena D, Grace K, Azarbarzin A, Messineo L, Hess L, et al.
Ann Am Thorac Soc
. 2023 Jul;
20(9):1326-1336.
PMID: 37411045
Loss of pharyngeal dilator muscle activity is a key determinant of respiratory events in obstructive sleep apnea (OSA). After the withdrawal of wakefulness stimuli to the genioglossus at sleep onset,...
6.
Genta P, Taranto-Montemurro L
Chest
. 2023 Apr;
163(4):749-750.
PMID: 37031981
No abstract available.
7.
Strassberger C, Hedner J, Sands S, Tolbert T, Taranto-Montemurro L, Marciniak A, et al.
Chest
. 2023 Jan;
163(5):1266-1278.
PMID: 36610664
Background: Emerging data suggest that determination of physiologic endotypic traits (eg, loop gain) may enable precision medicine in OSA. Research Question: Does a single-night assessment of polysomnography-derived endotypic traits provide...
8.
Sands S, Alex R, Mann D, Vena D, Terrill P, Gell L, et al.
Ann Am Thorac Soc
. 2022 Oct;
20(3):440-449.
PMID: 36287615
Sleep apnea is the manifestation of key endotypic traits, including greater pharyngeal collapsibility, reduced dilator muscle compensation, and elevated chemoreflex loop gain. We investigated how endotypic traits vary with obesity,...
9.
Messineo L, Gell L, Calianese N, Sofer T, Vena D, Azarbarzin A, et al.
Ann Am Thorac Soc
. 2022 Aug;
19(12):2062-2069.
PMID: 35947827
A low respiratory arousal threshold is a key endotype responsible for obstructive sleep apnea (OSA) pathogenesis. Pimavanserin is an antiserotoninergic capable of suppressing CO-mediated arousals without affecting the respiratory motor...
10.
Messineo L, Taranto-Montemurro L, Calianese N, Gell L, Azarbarzin A, Labarca G, et al.
Respirology
. 2022 Jul;
27(11):975-982.
PMID: 35811347
Background And Objective: The combination of the noradrenergic atomoxetine plus the anti-muscarinic oxybutynin acutely increased genioglossus activity and reduced obstructive sleep apnoea (OSA) severity. However, oxybutynin has shorter half-life than...